Record Details

Levetiracetam: review clinica ed economica di un nuovo antiepilettico

Farmeconomia. Health Economics and Therapeutic Pathways

View Archive Info
 
 
Field Value
 
Title Levetiracetam: review clinica ed economica di un nuovo antiepilettico
 
Creator Zaniolo, Orietta
Eandi, Mario
 
Subject Pharmacoeconomics; Health economics
 
Description Uncontrolled epilepsy has a significant negative impact on patient’s quality of life, on his emotional well-being and his social functioning. Seizure places an undue economic burden on the patient and community. The increased costs are direct and indirect (e.g.,inpatient care and loss of earnings associated with time lost from work). Levetiracetam is a new antiepileptic drug used as adjuntive therapy in the treatment of refractory epilepsy. Its nonconventional mechanism of action is not completely understood, but preclinical studies suggest that its antiepileptic action.may depend on a reversible, saturable and stereoselective binding site in CNS membranes. In this paper, we review the main clinical and economic data available in the scientific literature. Levetiracetam has a favourable pharmacokinetic profile characterised by rapid and nearly complete absorption, very low potential for drug interactions and a prolonged pharmacodynamic effect that permits twice-daily dosing. Several placebo-controlled clinical trials have demonstrated that its efficacy has enabled many patients who were refractory to treatment with other antiepileptic drugs to achieve long-term seizure freedom; furthermore in levetiracetam trials the frequency of adverse events is low and withdrawal rates are comparable with those of placebo. A cost/effectiveness analysis compared direct medical costs of levetiracetam add-on therapy with maintenance of standard therapy alone within the UK National Health Service. A 1-year dose escalation decision model was set up in refractory patients who failed to respond to two or more other currently available therapies, with seizure freedom selected as the measure of effectiveness. Available pharmacoeconomic data show that the incremental cost of treating patients with levetiracetam is low when compared with the benefits of seizure freedom, at least in the UK. Furthermore, current studies suggest that this antiepileptic drug has a potential as first-line treatment for many types of epilepsy and in many different patient populations.
 
Publisher SEEd Medical Publishers
 
Date 2004-06-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier https://journals.seedmedicalpublishers.com/index.php/FE/article/view/788
10.7175/fe.v5i2.788
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 5, No 2 (2004); 69-80
2240-256X
 
Language eng
 
Relation https://journals.seedmedicalpublishers.com/index.php/FE/article/view/788/883
 
Rights Copyright (c) 2004 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0